Program
avoralstat
Also written as “BCX4161”.
Its studies are mostly in Angioedemas, Hereditary · Macular Edema, led by BioCryst Pharmaceuticals.
Furthest: phase 3, since Nov 24, 20146 company-led studies, 0 open or running
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| BioCryst Pharmaceuticals | 60 open or running | phase 3since Nov 24, 2014 | Nov 5, 2013 | none ahead |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Nov 5, 2013First study: phase 2 study in Angioedemas, HereditaryFirst studyNCT01984788 · 24 enrolled · Germany, United Kingdom
- Apr 24, 2014Phase 1 study in Angioedemas, HereditaryNCT02125162 · 28 enrolled · United Kingdom
- Aug 14, 2014Phase 1 study in Angioedemas, HereditaryNCT02218294 · 7 enrolled · United Kingdom
- Nov 24, 2014Phase 3 study in Angioedemas, HereditaryNCT02303626 · 110 enrolled · United States, Belgium, Canada and more
- Jan 20, 2016Phase 3 study in Angioedemas, HereditaryNCT02670720 · 6 enrolled · Belgium, France
- Sep 26, 2025Phase 1 study in Diabetic Macular Edema (DME)NCT07228559 · 3 enrolled · United States, Australia
TargetBeta
KLKB1 →read by rule
“Plasma kallikrein inhibitor”ChEMBL 37, by rule
Studies
All 6 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07228559Diabetic Macular Edema (DME) · United States, Australia | 1 | Terminated | Apr 17, 2026 | 3 |
| NCT02670720Angioedemas, Hereditary · Belgium, France | 3 | Terminated | Feb 2016 | 6 |
| NCT02303626Angioedemas, Hereditary · United States, Belgium, Canada and more | 3 | Completed | Jan 2016 | 110 |
| NCT02218294Angioedemas, Hereditary · United Kingdom | 1 | Completed | Sep 2014 | 7 |
| NCT02125162Angioedemas, Hereditary · United Kingdom | 1 | Completed | Jul 2014 | 28 |
| NCT01984788Angioedemas, Hereditary · Germany, United Kingdom | 2 | Completed | May 2014 | 24 |
How it is read
Names in the registry
- “BCX4161”, 4 entries
- “avoralstat”, 2 entries
Conditions, from the studies’ own filings
- Angioedemas, Hereditary, 5 studies
- Macular Edema, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.